BioSpace News Archive

Erasca, Inc., a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, announced dosing of the first patient in the HERKULES-2 Phase 1b/2 trial evaluating ERAS-007 in combination with various agents in patients with advanced non-small cell lung cancer.

Vaccitech plc today announced that Bill Enright, Chief Executive Officer, will be presenting at the following investment conferences in September. Event: Morgan Stanley Healthcare Conference 2021

BetterLife Pharma Inc., an emerging biotechnology company primarily focused on developing compounds to treat neurological conditions, announces an agreement with Laboratory of Dr. John McCorvy at the Medical College of Wisconsin for TD-0148A preclinical receptor binding studies.

PMV Pharmaceuticals, Inc. today announced the appointment of Tim Smith as Senior Vice President, Head of Corporate Development.

Krystal Biotech Inc. today announced that it will present data on its lead product candidate beremagene geperpavec (B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB) at the upcoming DEBRA International Conference 2021.

Marrone Bio Innovations, Inc. is on track to submit MBI-306, its next generation nematicide/insecticide, to regulatory authorities in the United States within the coming weeks.

Rani Therapeutics Holdings, Inc. today announced the appointment of Eric Groen as General Counsel.

Miromatrix Medical Inc., a life sciences company pioneering a novel technology for bioengineering fully transplantable organs to help save and improve patients’ lives, announced the hiring of Dr. John Barry as Vice President of Research and Development.

Veranome Biosystems announced commercial availability of the VSA-1 instrument for highly multiplexed, single cell spatial analysis.

Icosavax, Inc. (NASDAQ: ICVX), today announced the initiation of a Phase 1/1b clinical trial of IVX-121, a VLP displaying a Respiratory Syncytial Virus (RSV) stabilized pre-fusion F antigen, in healthy adults and older adults.